The Cambridge biotechnology company Genzyme Corp. has launched its kidney disease treatment Renvela.
The Food and Drug Administration approved the drug in October. Itís a new version of the kidney disease drug Renagel, in use since 1998.
Renvela is approved to control serum phosphorus in patients with chronic kidney disease who are on dialysis. The body uses the chemical to get energy from food.
Genzyme is also seeking approval for Renvela in Europe and for US patients who are not going through dialysis treatment.